Wells Fargo’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Wells Fargo’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$89	Sell	1 -1	-50%	-$83	﹤0.01%	6517
2025 Q4	$145	Buy	2 +1	+100%	+$74	﹤0.01%	6406
2025 Q3	$67	Buy	+1	New	+$54	﹤0.01%	6441
2025 Q2	–	Sell	-1	Closed	-$44	–	6802
2025 Q1	$29	Sell	1 -1	-50%	-$54	﹤0.01%	6564
2024 Q4	$77	Buy	2 +1	+100%	+$59	﹤0.01%	6446
2024 Q3	$35	Hold	1	–	–	﹤0.01%	6416
2024 Q2	$41	Hold	1	–	–	﹤0.01%	6350
2024 Q1	$81	Hold	1	–	–	﹤0.01%	6710
2023 Q4	$43	Sell	1 -1,849	-100%	-$86.7K	﹤0.01%	6961
2023 Q3	$88.7K	Sell	1,850 -1	-0.1%	-$51	﹤0.01%	4845
2023 Q2	$96.3K	Buy	1,851 +1	+0.1%	+$55	﹤0.01%	5064
2023 Q1	$100K	Buy	+1,850	New	+$104K	﹤0.01%	4797

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

KFS

Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Wells Fargo's BIB Position: Q1 2026 in Review

Wells Fargo reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 50% in Q1 2026, selling an estimated $83 and leaving 1 share worth $89. The position accounts for ﹤0.01% of the portfolio, ranked #6517.

Wells Fargo first reported a position in BIB in Q1 2023 and has held it in 12 quarters since. The position peaked at $100K in Q1 2023. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

Wells Fargo held 1 share of ProShares Ultra NASDAQ Biotechnology worth $89 as of Q1 2026.
Wells Fargo sold 1 ProShares Ultra NASDAQ Biotechnology share in Q1 2026, an estimated $83.
ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6517 holding.
Wells Fargo first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2023 and has held it in 12 quarters since.
Wells Fargo's ProShares Ultra NASDAQ Biotechnology position peaked at $100K in Q1 2023.
23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.